Incidence of Disseminated Tuberculosis in BCG-Vaccinated vs. Non-Vaccinated Children
BCG vaccination significantly reduces the incidence of disseminated tuberculosis in children, with vaccinated children showing approximately 4-5 times lower rates of disseminated disease (meningitis and miliary TB) compared to unvaccinated children.
Key Epidemiological Data
The most robust evidence comes from a South African study comparing different BCG vaccination strategies 1. Among children under 2 years:
- Unvaccinated children: 29.2% developed disseminated disease
- BCG-vaccinated children (combined groups): 6.6% developed disseminated disease
- Relative risk reduction: 4.4-fold (95% CI 2.7-6.7)
When comparing specific vaccination methods 1:
- Percutaneous Tokyo 172 BCG: 8.6% disseminated disease
- Intradermal Danish 1331 BCG: 4.7% disseminated disease (relative risk 0.54; 95% CI 0.40-0.72)
Pattern of Disease in Vaccinated vs. Unvaccinated Children
A comparative study of 100 children found 2:
- Vaccinated group: 24% had serious forms (meningitis, miliary, disseminated TB)
- Unvaccinated group: 22% had serious forms
- While the proportions were similar (p>0.05), morbidity was notably less severe in the vaccinated group
Another study from South Africa demonstrated that BCG vaccination appeared to diminish dissemination incidence, particularly tuberculous meningitis, and reduced mortality 3.
Critical Context: Immunocompromised Children
Important caveat: The protective benefit must be weighed against the risk of disseminated BCG infection (BCGosis) in immunocompromised children 4:
- Fatal disseminated BCG disease occurs at 0.06-1.56 cases per million vaccine doses
- Deaths occur primarily in immunocompromised individuals
- HIV-infected children and those with primary immunodeficiencies (SCID, CGD) are at highest risk 5
The CDC guidelines explicitly state: BCG vaccination is not recommended for children infected with HIV or those with known immunodeficiency 4.
Age-Specific Considerations
Swedish data tracking BCG coverage changes showed 6:
- Among 85 tuberculosis cases in Swedish-born children, 45 were symptomatic
- Only 3 cases had disseminated tuberculosis
- The effectiveness of selective BCG vaccination was estimated at 0.82 (95% CI 0.38-0.95)
Clinical Algorithm for Decision-Making
Before BCG vaccination, assess:
- HIV status and immune function - Absolute contraindication if immunocompromised
- Family history of primary immunodeficiency - Particularly in populations with high consanguinity 5
- TB exposure risk - High-risk settings warrant vaccination if immunocompetent
- Age and nutritional status - Severe malnutrition increases risk of disseminated disease even with vaccination 2
For immunocompetent children in high TB prevalence areas:
- BCG vaccination at birth or early infancy provides substantial protection against disseminated forms
- The 4-5 fold reduction in disseminated disease outweighs the minimal risk of BCGosis (0.06-1.56 per million doses)
For immunocompromised or high-risk infants:
- Delay vaccination until immune status confirmed 7, 8
- Consider deferring until 6-12 months when screening can be completed
- No BCG if symptomatic HIV infection or known severe immunodeficiency 4
Bottom Line
The evidence consistently demonstrates that BCG vaccination reduces disseminated tuberculosis incidence by approximately 75-80% in immunocompetent children, with the most dramatic protection against tuberculous meningitis and miliary disease. However, this benefit is completely reversed in immunocompromised children, where BCG itself can cause fatal disseminated disease. Screen for immunodeficiency before vaccinating, particularly in populations with high consanguinity rates or known HIV prevalence 5.